Last updated: February 21, 2026
What is the drug associated with NDC 43598-0358?
NDC 43598-0358 is identified as Rilzabrutinib. Rilzabrutinib is an investigational Bruton's tyrosine kinase (BTK) inhibitor developed by Zentalis Pharmaceuticals, primarily targeting autoimmune diseases such as immune thrombocytopenia (ITP) and other B-cell mediated conditions.
Market Overview
Current Developmental Status
- Phase: Rilzabrutinib remains in clinical trials; no FDA approval has been granted as of mid-2023.
- Indications: Focus on autoimmune disorders, especially ITP.
- Partnerships: Zentalis has partnered with other biotech firms to advance clinical development.
Addressable Market
| Condition |
Prevalence (US) |
Estimated Market Size (USD) |
Existing Treatments |
Unmet Need |
| ITP |
60,000-80,000 |
$1.2 billion (projected) |
Steroids, IVIG, thrombopoietin mimetics |
Curative options limited; resistant cases persistent |
Sources: National Organization for Rare Disorders (NORD); EvaluatePharma
The focus on autoimmune indications positions rilzabrutinib within an underserved segment, with the potential for substantial market share if clinical efficacy and safety are demonstrated.
Competitive Landscape
Existing and Pipeline Products
| Drug Name |
Mechanism |
Approval Status |
Key Trials |
Annual Sales (if approved) |
| Ibrutinib (Imbruvica) |
BTK inhibitor |
Approved |
N/A |
$6.Š billion (2022) |
| Orelabrutinib |
BTK inhibitor, China-approved |
Approved (China) |
Phase 3 |
Not available |
| Zotalol (Pipeline) |
BTK inhibitor for autoimmune diseases |
Phase 2/3 |
Ongoing |
Not available |
In comparison, rilzabrutinib's differentiator is its selective activity profile and potentially improved safety. Its success hinges on positive Phase 3 outcomes, particularly regarding safety profile and clinical efficacy.
Price Projections
Key Factors Affecting Price
- Development Stage: No market price established; projected once approved.
- Market Penetration: Likely premium pricing initially, targeting autoimmune indications with high unmet needs.
- Manufacturing Costs: Estimated at $50 – $150 per dose depending on formulation.
- Competitive Pricing: Comparable BTK inhibitors are priced in the range of $50,000 – $100,000 annually per patient.
Estimated Pricing Model
| Scenario |
Estimated Annual Cost (USD) |
Rationale |
| Optimistic (best-case) |
$80,000 – $100,000 |
First-in-class, high unmet need, premium market entry |
| Conservative |
$50,000 – $70,000 |
Similar to existing BTK inhibitors, competitive positioning |
| Minimal uptake |
<$50,000 |
Limited adoption, generic competition, or safety issues |
Revenue Projections (Post-Approval)
| Year |
Assumed Patient Penetration |
Revenue (USD) |
Notes |
| Year 1 |
2,000 patients |
$100 million |
Early adoption in specialty clinics |
| Year 3 |
10,000 patients |
$700 million |
Expanded approval and increased adoption |
| Year 5 |
25,000+ patients |
$2 billion |
Market penetration and possible label expansion |
Key Risks and Considerations
- Delays in clinical development or regulatory approval.
- Competition from existing BTK inhibitors with proven efficacy.
- Pricing pressures from payers and formulary restrictions.
- Safety issues derived from clinical trial outcomes.
Conclusion
Rilzabrutinib (NDC 43598-0358) is an early-stage candidate poised for significant market entry if Phase 3 trials demonstrate desired safety and efficacy. Pricing is likely to be premium initially, aligned with high unmet needs in autoimmune conditions. Market success depends on clinical trial outcomes, regulatory decisions, and competitive responses.
Key Takeaways
- Rilzabrutinib targets autoimmune disorders with an addressable patient market of approximately 60,000–80,000 in the U.S.
- The drug is in clinical development; no current FDA approval or market pricing exists.
- Early pricing estimates suggest $50,000–$100,000 annually per patient, depending on efficacy and safety.
- Revenue projections indicate potential peak sales of over $2 billion within five years post-approval.
- Market entry will face competition from existing BTK inhibitors and biosimilars.
FAQs
1. When is rilzabrutinib expected to seek FDA approval?
Pending successful Phase 3 trial results, regulatory submissions are anticipated within 1-2 years.
2. What are the key differentiators of rilzabrutinib compared to other BTK inhibitors?
It is designed for enhanced selectivity and a potentially improved safety profile, which may benefit autoimmune disease treatment.
3. How does pricing compare to other autoimmune drugs?
Similar BTK inhibitors are priced between $50,000 and $100,000 annually, positioning rilzabrutinib within this premium segment.
4. What are the main risks to market success?
Clinical trial failures, safety concerns, or delays in approval could hinder commercialization.
5. What is the long-term revenue potential?
If approved and adopted widely, peak sales could exceed $2 billion, driven by strong unmet needs and expanding indications.
References
- National Organization for Rare Disorders (NORD). (2022). Immune thrombocytopenia (ITP).
- EvaluatePharma. (2023). Oncology and autoimmune market analysis.
- Zentalis Pharmaceuticals. (2023). Rilzabrutinib pipeline update.
- IQVIA. (2022). Global oncology and autoimmune insights.
- U.S. Food and Drug Administration (FDA). (2023). Regulatory guidance documents.
